Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
• T cell dysregulation is implicated in MM pathogenesis and progression.
• Understanding immune cell dynamics is crucial for monitoring MM activity.

Purpose of the Study:

• To investigate T cell subset alterations in multiple myeloma patients.
• To examine the relationship between T cell phenotypes and disease activity markers.
• To explore the role of interleukin-16 (IL-16) in MM-associated immune changes.

Main Methods:

• Flow cytometry was used to analyze T cell populations and human leukocyte antigen (HLA)-DR expression.
• Serum levels of interleukin-16 (IL-16) were quantified.
• Comparisons were made between MM patients (stratified by stage) and healthy controls.

Main Results:

• A decreased CD4/CD8 T cell ratio was observed in MM patients.
• Increased HLA-DR expression on CD8+ T cells correlated significantly with the reduced CD4/CD8 ratio.
• Serum IL-16 levels were significantly elevated in stage III MM patients compared to controls.

Conclusions:

• The findings suggest that T cell phenotypic changes, including decreased CD4/CD8 ratio and increased HLA-DR on CD8+ T cells, are associated with multiple myeloma.
• Elevated IL-16 levels in advanced MM may contribute to CD4+ T cell reduction via CD8+ T cell activation.
• These immunological markers may serve as valuable indicators of multiple myeloma disease activity.